Author/Authors :
Matsumura، نويسنده , , Akira and Shibata، نويسنده , , Yasushi and Yamamoto، نويسنده , , Tetsuya and Yoshida، نويسنده , , Fumiyo and Isobe، نويسنده , , Tomonori and Nakai، نويسنده , , Kei and Hayakawa، نويسنده , , Yoshinori and Kiriya، نويسنده , , Minako and Shimojo، نويسنده , , Nobuhiro and Ono، نويسنده , , Koji and Sakata، نويسنده , , Isao and Nakajima، نويسنده , , Susumu and Okumura، نويسنده , , Masafumi and Nose، نويسنده , , Tadao، نويسنده ,
Abstract :
A new boronated porphyrin compound (STA-BX909) was developed as a possible agent for boron neutron capture therapy. The boron concentration was measured by an in vivo rat experimental brain tumor model and an in vitro cell culture study. This agent was compared to sodium borocaptate (BSH) which has been used in clinical trials of boron neutron capture therapy. In the 9L rat brain tumor model, STA-BX909 achieved a higher boron tumor/blood ratio 24 h after injection in comparison to BSH. A boron concentration study in cultured glioma cell lines (U-251, U-87, 9L) demonstrated an increased boron concentration as a function of exposure time to STA-BX909, while the boron concentration remained stable with increasing exposure time to BSH. Use of a colony forming assay with thermal neutron irradiation revealed more cytotoxicity with STA-BX909 than BSH when the same concentration of 10B was administered. We concluded that STA-BX909 may be an effective drug for use in boron neutron capture therapy and that it merits further investigation.
Keywords :
Glioma , Boronated porphyrin , Neutron capture therapy , 9L
